Article

ForbesForbes on 2022-07-25 15:23

Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million

The deal values Zymergen at a fraction of its $3 billion valuation at Zymergen’s IPO last April.

Related news